Melanoma Coverage from Every Angle
Advertisement
Advertisement

Vemurafenib Plus Cobimetinib in BRAF -Mutant Melanoma: 5-Year BRIM7 Follow-up

By: Joshua Swore
Posted: Monday, March 9, 2020

In Clinical Cancer Research, the 5-year follow-up results of the phase Ib BRIM7 trial demonstrated improved survival outcomes with the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib in a subset of patients with advanced BRAF V600–mutated melanoma. According to Antoni Ribas, MD PhD, of the University of California Los Angeles, and colleagues, “Long-term treatment achieved late conversions from partial to complete responses, and it did not result in unexpected long-term toxicities.”

A total of 129 patients with BRAF-mutant melanoma were enrolled in the study. Patients were separated into a BRAF inhibitor–naive cohort (n = 63) and a vemurafenib-monotherapy cohort (n = 66). Based on the results of the original study, the researchers chose to use two regimens for the present study: vemurafenib at 720 mg or 960 mg twice daily combined with cobimetinib at 60 mg/day for 21 days on and 7 days off.

The extended study results found that the median overall survival was 31.8 month in the BRAF-naive cohort (95% confidence interval = 24.5 months to not estimable) and 8.5 months in the vemurafenib monotherapy–progressive disease cohort (95% confidence interval = 6.7–11.1 months). Overall survival plateaued at 39.2% at 4- and 5-year follow-up in the BRAF-naive cohort, whereas in the vemurafenib monotherapy–progressive disease cohort, overall survival plateaued at 14% at 3-year follow-up.

The researchers found no new toxicities compared with the original study In addition, “there was no increase in the frequency of symptomatic MEK inhibitor class-effect adverse events,” they noted. The authors indicated the results of this follow-up suggest that a subpopulation of patients with BRAF-mutated melanoma treated with a regimen of vemurafenib and cobimetinib may obtain a positive long-term outcome.

Disclosure: For full disclosures of the study authors, visit clincancerres.aacrjournals.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.